Among the commercially available GLP-1 RAs, only exenatide (EX) and liraglutide have been recommended for PCOS [27], and so far few randomized controlled trials (RCTs) have shown that liraglutide improves ovulation or pregnancy outcomes, making EX more promising for clinical application. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.